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We are making progresses in the treatment of both early and
advanced solid tumours. Vaccines are available and demonstrate
efficacy in the prevention of hepatocellular carcinoma, cervical
and head and neck carcinomas. The use of adjuvant or neoadju-
vant medical treatments in breast, colon, rectal, ovarian and gas-
tric cancer produce additional cure rates of 10–30% (on top of
those afforded by surgery alone). And chemotherapy, hormonal
treatment, and biologic agents have improved the outcome of
metastatic cancer in every solid tumour, including the most
refractory (renal cell, GIST, hepatocellular carcinomas), so that
the classical distinction operated 10–15 years ago of advanced
cancers into ‘resistant, sensitive and curable’ tumours has been
revolutionized. However resistance to medical treatments contin-
ues to be the main reason for failures in the advanced setting, and
this is more pronounced amongst certain tumours where the pro-
gresses have been much more limited: melanoma, biliary tract
cancer, oesophageal, non small cell lung cancer, brain tumours,
cervical, endometrial cancers and soft tissue sarcomas. There
are 4 main challenges for the near future: a better classification
of tumours, no longer based upon the morphology, but on their
molecular characteristics; a simplification and acceleration of
the drug development process; a more courageous drug design
and a drug approval process that is more focused on the clinical
relevance of the data rather than on their statistical significance.
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